Chardan Capital Has Negative View of Femasys FY2024 Earnings

Femasys Inc. (NASDAQ:FEMY) – Equities research analysts at Chardan Capital decreased their FY2024 earnings per share (EPS) estimates for Femasys in a research report issued to clients and investors on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will earn ($0.84) per share for the year, down from their prior forecast of ($0.79). Chardan Capital currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.49) EPS.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Femasys in a report on Tuesday, November 12th.

Femasys Trading Down 2.2 %

Shares of FEMY opened at $0.93 on Monday. Femasys has a 12-month low of $0.73 and a 12-month high of $2.40. The firm has a market capitalization of $21.34 million, a P/E ratio of -1.15 and a beta of -2.83. The firm has a 50-day moving average price of $1.15 and a 200 day moving average price of $1.14. The company has a current ratio of 3.94, a quick ratio of 5.93 and a debt-to-equity ratio of 0.86.

Institutional Investors Weigh In On Femasys

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aljian Capital Management LLC purchased a new position in shares of Femasys during the 3rd quarter worth $27,000. XTX Topco Ltd lifted its position in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. Geode Capital Management LLC boosted its stake in Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the period. Finally, CM Management LLC increased its position in shares of Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after acquiring an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.